During the last session, Matinas Biopharma Holdings Inc (AMEX:MTNB)’s traded shares were 32346.0, with the beta value of the company hitting 1.55. At the end of the trading day, the stock’s price was $0.60, reflecting an intraday gain of 2.39% or $0.01. The 52-week high for the MTNB share is $21.50, that puts it down -3483.33 from that peak though still a striking 20.0% gain since the share price plummeted to a 52-week low of $0.48. The company’s market capitalization is $3.05M, and the average trade volume was 400.02K shares over the past three months.

Matinas Biopharma Holdings Inc (AMEX:MTNB) trade information

Matinas Biopharma Holdings Inc (MTNB) registered a 2.39% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 2.39% in intraday trading to $0.60, hitting a weekly high. The stock’s 5-day price performance is 3.45%, and it has moved by -14.29% in 30 days. Based on these gigs, the overall price performance for the year is -94.20%.

Matinas Biopharma Holdings Inc (MTNB) estimates and forecasts

In the rating firms’ projections, revenue will decrease -100.00% compared to the previous financial year.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 7.12%. While earnings are projected to return 26.18% in 2025.

MTNB Dividends

Matinas Biopharma Holdings Inc is due to release its next quarterly earnings in March. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

The next largest institutional holding, with 9.32 million shares, is of VANGUARD GROUP INC’s that is approximately 4.2869% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $1.48 million.